Nov 28, 2018

QuiaPEG Pharmaceuticals Holding AB (publ) develops improved and patentable versions of clinically validated or approved drugs, known as biobetters. This is based on the company's proprietary patent-protected technology platform, Uni-Qleaver®, which allows selection of a release time for the drug through a controllable chemical coupling unit. After receiving positive pre-clinical trial results, the company has chosen its first drug project, peg-liraglutide (QPG- 1029), which has blockbuster1 potential for the indications diabetes and obesity.

Download press release (PDF)
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 54 Uppsala
+46 (0) 70 693 12 53

User terms & privacy policy
Send a message